Artificial intelligence (AI) is revolutionizing the healthcare industry, with potential to make dramatic improvements in clinical care and provider efficiency. By 2021, Accenture estimates the health AI market will reach $6.6 billion as the industry seeks to improve cost, quality and access to care.
Some of the most dramatic growth of AI will be in medical imaging specialties, including neurology, cardiovascular, lung and liver. However, a recent report estimates that 15 percent of the market share will be focused on AI for breast.
For breast health, specifically, more and more providers are turning to digital breast tomosynthesis (DBT) – or 3D mammography – as their preferred method for screening and diagnosis of early-stage breast cancer. Unlike traditional 2D mammograms, which result in only four images to analyze, DBT produces large data sets comprised of hundreds of images, providing radiologists with greater clarity and detail. In contrast, this requires significantly more time to review and interpret each breast exam.
This is where AI technology can be extremely impactful. Capitalizing on the benefits of AI in breast imaging, iCAD, a global medical technology leader providing innovative cancer detection and therapy solutions, recently introduced its latest solution for DBT, ProFound AI™. Currently available for use with leading DBT systems in the U.S., Canada and Europe, the solution is a high-performance, deep-learning, cancer detection and workflow solution delivering critical benefits to radiologists, their facilities and their patients.
ProFound AI has been proven to improve cancer detection rates by an average of 8 percent and decrease unnecessary patient recall rates by an average of 7 percent. Furthermore, the new technology is trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the algorithm’s confidence that a specific finding or case is malignant based on the large dataset of clinical images used to train the algorithm.
In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed that ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2D to 3D mammography.
iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. We work passionately to provide precise, powerful healthcare solutions expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes. iCAD offers a comprehensive range of artificial intelligence and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. For more information, visit www.icadmed.com or www.xoftinc.com or contact Diane Clifford, director of marketing, at email@example.com.
At this year’s European Congress of Radiology (ECR) in Vienna, Austria, attendees can explore iCAD’s full suite of Breast Health Solutions for advanced cancer detection built on artificial intelligence, including ProFound AI. Interested conference participants can stop by X1, booth AI-17 or register for a meeting or demonstration to better understand how the solutions can best address the challenges faced by all healthcare facilities, and most importantly, deliver quality care to your patients.
* Contents provided by iCAD and adapted by the ESR office